Gemcitabine based treatment is currently a standard first line treatment for patients with
advanced pancreatic cancer, however overall survival remains poor, and few options are …

Cancer heterogeneity and microenvironmental aspects within a tumor are considered key
factors influencing resistance of carcinoma cells to distinct chemotherapeutical agents. We …

The current treatment of choice for metastatic pancreatic cancer involves single-agent
gemcitabine or a combination of gemcitabine with capecitabine or erlotinib (a tyrosine …

Pancreatic cancer is the fourth leading cause of cancer‐related death in the United States.
While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced …

Introduction: Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in
the US and Europe, and the lethality of this cancer is demonstrated by the fact that the …

Objectives Gemcitabine resistance (GR) is one of the critical issues for therapy for pancreatic
cancer, but the mechanism still remains unclear. Our aim was to increase the understanding …

Objective Desmoplasia and hypovascularity are thought to impede drug delivery in
pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have …

Introduction: Pancreatic cancer is a complex disease, with an extremely poor response to
chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might …

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease.
Gemcitabine (GEM) is used as the gold standard drug in PDAC treatment. However, due to …